Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Ryan

Showing results (81-90 of 274) with videos related to

Pageof 28
Sort By:
American Journal of Clinical Oncology|February 8, 2006
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancerA David McCollum, Bingyan Wu, Jeffrey W Clark, et al.
Endocrine-Related Cancer|June 28, 2012
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsJennifer A Chan, David P Ryan, Andrew X Zhu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2009
Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or olderDavid T Miyamoto, Harvey J Mamon, David P Ryan, et al.
Digestive Diseases and Sciences|June 29, 2007
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancerJeffrey A Meyerhardt, Andrew X Zhu, Keith Stuart, et al.
International Journal of Radiation Oncology, Biology, Physics|November 25, 2010
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapyLisa A Kachnic, Henry K Tsai, John J Coen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II studyPeter S Kozuch, Caio Max Rocha-Lima, Tomislav Dragovich, et al.
International Journal of Radiation Oncology, Biology, Physics|March 23, 2012
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancerRonald C Chen, Harvey J Mamon, Marek Ancukiewicz, et al.
Virchows Archiv : an International Journal of Pathology|March 21, 2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino, Jeffrey A Meyerhardt, Takako Kawasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumorsMichael V Seiden, Shu-Wing Ng, Jeffrey G Supko, et al.
American Journal of Clinical Oncology|March 1, 2014
The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With RadiationJonathan D Schoenfeld, Jennifer Y Wo, Harvey J Mamon, et al.
Pageof 28

Showing results (81-90 of 274) with videos related to

Sort By:
Pageof 28
American Journal of Clinical Oncology|February 8, 2006
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancerA David McCollum, Bingyan Wu, Jeffrey W Clark, et al.
Endocrine-Related Cancer|June 28, 2012
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsJennifer A Chan, David P Ryan, Andrew X Zhu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2009
Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or olderDavid T Miyamoto, Harvey J Mamon, David P Ryan, et al.
Digestive Diseases and Sciences|June 29, 2007
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancerJeffrey A Meyerhardt, Andrew X Zhu, Keith Stuart, et al.
International Journal of Radiation Oncology, Biology, Physics|November 25, 2010
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapyLisa A Kachnic, Henry K Tsai, John J Coen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II studyPeter S Kozuch, Caio Max Rocha-Lima, Tomislav Dragovich, et al.
International Journal of Radiation Oncology, Biology, Physics|March 23, 2012
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancerRonald C Chen, Harvey J Mamon, Marek Ancukiewicz, et al.
Virchows Archiv : an International Journal of Pathology|March 21, 2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino, Jeffrey A Meyerhardt, Takako Kawasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumorsMichael V Seiden, Shu-Wing Ng, Jeffrey G Supko, et al.
American Journal of Clinical Oncology|March 1, 2014
The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With RadiationJonathan D Schoenfeld, Jennifer Y Wo, Harvey J Mamon, et al.
Pageof 28